Abstract 311P
Background
Alectinib demonstrated significantly improved clinical outcomes in patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small-cell lung cancer (NSCLC) in a randomized Phase III trial (ALEX). There is no study examining long-term health and economic outcomes of this first-line treatment of ALK+ advanced NSCLC compared with chemotherapy that has been a standard of care in Thailand.
Methods
A partitioned survival model consisted of 3 health states (progression-free survival, post-progression survival, and death) was developed. Costs were obtained from literature from the Thai setting. Clinical outcomes were obtained from a network meta-analysis of related published trials. All outcomes and costs were estimated from a provider perspective over a 35-year time horizon and discounted at 3% annually. One-way and probabilistic sensitivity analyses were carried out to determine robustness of the findings. The Thai willingness-to-pay (WTP) threshold at $4,520/quality-adjusted life-years (QALY) was applied.
Results
The estimated mean overall survivals were 5.97 years for alectinib and 3.3 years for chemotherapy. The alectinib and chemotherapy provided 3.75 and 1.68 QALY, respectively. The total lifetime costs for alectinib and chemotherapy were $105,254 and $24,068. The incremental cost-effectiveness ratio (ICER) were $30,390/life-year and $39,205/QALY.
Conclusions
The model showed that alectinib has provided almost double increases in clinical benefits over chemotherapy as the current standard of care. Alectinib has been a standard of care in many settings where the treatment is demonstrated as a cost-effective option. Alectinib for treating Thai patients exceeds the current WTP threshold and it would result in limited access to this treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
291P - Assessment of nutritional status in cancer patients using patient generated subjective global assessment screening tool
Presenter: Anuj K. C.
Session: Poster viewing 04
293P - Generic dabigatran for cancer-associated venous thromboembolism: Real-world data
Presenter: Fen Saj
Session: Poster viewing 04
294P - Cross-sectional analysis on cancer-related distress, belief in alternative medicine among cancer patients and attendants visiting a tertiary care center in Northern India
Presenter: Amit Sehrawat
Session: Poster viewing 04
296P - Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
Presenter: Yi-Long Wu
Session: Poster viewing 04
297P - Transbronchial microwave ablation of early lung cancers and lung oligometastases: Mid-term results
Presenter: Joyce Chan
Session: Poster viewing 04
298P - Does trisegmentectomy have functional benefit over lobectomy? Comparative analysis of changes in lung function and volumetry among stage IA non-small cell lung cancer patients
Presenter: sumin shin
Session: Poster viewing 04
299P - Furmonertinib as adjuvant therapy in EGFR-mutated non-small cell lung cancer following radical lung cancer surgery
Presenter: Qingyi Zhang
Session: Poster viewing 04
300P - Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer
Presenter: Xin Shang
Session: Poster viewing 04
301P - Oxygen desaturation during 6-min walk test: Implications for postoperative complications in non-small cell lung cancer patients with impaired lung function
Presenter: Hye Yun Park
Session: Poster viewing 04